Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial

Paul D. Brown(Mayo Clinic in Arizona), Karla V. Ballman(Alliance Data (United States)), Jane H. Cerhan(Mayo Clinic in Arizona), S. Keith Anderson(Alliance Data (United States)), Xiomara W. Carrero(Alliance Data (United States)), Anthony Whitton(Juravinski Cancer Centre), Jeffrey Greenspoon(Juravinski Cancer Centre), Ian F. Parney(Mayo Clinic in Arizona), Nadia N. Laack(Mayo Clinic in Arizona), Jonathan B. Ashman(WinnMed), Jean-Paul Bahary(Hôpital Notre-Dame), Costas G. Hadjipanayis(Mount Sinai Beth Israel), James J. Urbanic(University of California, San Diego), Fred G. Barker(Massachusetts General Hospital), Elana Farace(Pennsylvania State University), Deepak Khuntia(Varian Medical Systems (United States)), Caterina Giannini(Mayo Clinic in Arizona), Jan C. Buckner(Mayo Clinic in Arizona), Evanthia Galanis(Mayo Clinic in Arizona), David Roberge(Hôpital Notre-Dame)
The Lancet Oncology
July 4, 2017
Cited by 1,183Open Access
Full Text

Abstract


Related Papers